LYEL — Lyell Immunopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $731.18m
- $411.56m
- $0.06m
- 24
- 8
- 100
- 39
Annual cashflow statement for Lyell Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -204 | -250 | -183 | -235 | -343 |
| Depreciation | |||||
| Non-Cash Items | 39.6 | 106 | 77.6 | 47.3 | 164 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.336 | 4.01 | -82 | 3.42 | -3.12 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -161 | -126 | -170 | -164 | -162 |
| Capital Expenditures | -51.5 | -65.5 | -24.3 | -2.69 | -31.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -222 | -56.1 | 12.7 | 187 | 154 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -274 | -122 | -11.5 | 184 | 122 |
| Financing Cash Flow Items | — | — | -0.461 | -0.457 | -0.076 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 477 | 401 | 10.6 | 1.74 | 1.33 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 42.4 | 153 | -170 | 22.1 | -38.6 |